-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News, April 16 Recently, the Fujian Provincial Medical Insurance Bureau issued the "Notice on Announcement of the Second Batch of Medical Insurance Key Monitoring Drugs and List of Key Drugs".
Among them, 10 medical insurance drugs are under key monitoring and 59 are under special attention; the two types of lists are subject to dynamic management.
For key monitoring drugs, finding how to solve the survival crisis is the kingly way.
Among them, 10 medical insurance drugs are under key monitoring and 59 are under special attention; the two types of lists are subject to dynamic management.
For key monitoring drugs, finding how to solve the survival crisis is the kingly way.
Re-clinical evaluation
The first thing to do is to find out the problem with the drug being monitored.
For example, in my country, Oxiracetam is approved for memory and intellectual impairment caused by mild to moderate vascular dementia, senile dementia, and traumatic brain injury.
However, in the United States, Oxiracetam has been withdrawn.
Phase II clinical trial for the treatment of Alzheimer's disease.
Another example is the use of auxiliary medicines, which are likely to cause doctor-patient disputes.
In addition to prescribing medicines, doctors need to be cautious, and it is also necessary to conduct a new clinical evaluation.
For example, in my country, Oxiracetam is approved for memory and intellectual impairment caused by mild to moderate vascular dementia, senile dementia, and traumatic brain injury.
However, in the United States, Oxiracetam has been withdrawn.
Phase II clinical trial for the treatment of Alzheimer's disease.
Another example is the use of auxiliary medicines, which are likely to cause doctor-patient disputes.
In addition to prescribing medicines, doctors need to be cautious, and it is also necessary to conduct a new clinical evaluation.
In addition, a re-clinical evaluation may allow the unique value of the drug to be found in the clinical pathway, or it may be possible to lock in a more effective treatment plan in the new study of combination drugs.
Open up a "second battlefield"
For pharmaceutical companies, the restricted use of drugs due to key monitoring, ranging from a sharp decline in sales performance, to a rupture of the capital chain and falling to death.
However, the East is not bright and the West is bright.
In addition to public-level hospitals and public primary hospitals, there are also private hospitals, clinics, chain pharmacies , and single pharmacies.
Restricted varieties can open up a "second battlefield" and enter other channels.
First, consider switching from medical insurance drugs to self-funded drugs in public hospitals.
If it is an oral medicine that has been sold in hospitals for many years and has a solid market basis, it can be transferred to OTC channels.
However, the East is not bright and the West is bright.
In addition to public-level hospitals and public primary hospitals, there are also private hospitals, clinics, chain pharmacies , and single pharmacies.
Restricted varieties can open up a "second battlefield" and enter other channels.
First, consider switching from medical insurance drugs to self-funded drugs in public hospitals.
If it is an oral medicine that has been sold in hospitals for many years and has a solid market basis, it can be transferred to OTC channels.
In addition, it is possible to consider direct chain pharmacies with more than 30 stores.
Directly-operated chains have strong execution in price control, channel protection, and sales traceability, and can better cooperate with manufacturers to implement their sales intentions.
Directly-operated chains have strong execution in price control, channel protection, and sales traceability, and can better cooperate with manufacturers to implement their sales intentions.
Private hospitals, private clinics
Part of the restricted medicines do not completely lose their vitality.
On the contrary, they may be very useful in private hospitals and private clinics.
At present, the development threshold of private hospitals and private clinics is low, and the base is huge.
On the contrary, they may be very useful in private hospitals and private clinics.
At present, the development threshold of private hospitals and private clinics is low, and the base is huge.
The author believes that certain drugs with the potential to improve the quality of life (such as compound coenzyme for injection, calf serum deproteinized injection, troxerutin cerebroprotein hydrolysate injection), or varieties with fewer manufacturers (such as cerebroside and carnosine) Injection, invert sugar electrolyte injection, etc.
), these channels can be considered.
If medical insurance does not pay, pharmaceutical companies can also seek support from commercial insurance.
), these channels can be considered.
If medical insurance does not pay, pharmaceutical companies can also seek support from commercial insurance.
Change the route of administration
For restricted Chinese patent medicine injections, it is possible to consider changing the route of administration, new routes of administration such as transdermal absorption, enema, atomization, spraying and so on.
Some of the restricted Chinese medicine injections are from well-known families.
They have good production technology and purification technology.
A good horse is equipped with a good saddle.
The new drug delivery method can not only solve the sales problem of restricted medicines, but also improve the curative effect.
Some of the restricted Chinese medicine injections are from well-known families.
They have good production technology and purification technology.
A good horse is equipped with a good saddle.
The new drug delivery method can not only solve the sales problem of restricted medicines, but also improve the curative effect.
Adjust the variety structure
Pharmaceutical production enterprises to change totally dependent on a single product big habit pulled up the performance.
It is necessary to keep abreast of the market pulse, adjust its product line in time, continue to introduce new ones, "sell a batch, market a batch, develop a batch", and develop drugs with real therapeutic value.
It is necessary to keep abreast of the market pulse, adjust its product line in time, continue to introduce new ones, "sell a batch, market a batch, develop a batch", and develop drugs with real therapeutic value.
The wind started at the end of Qingping.
The restriction of drugs will lead to a cliff-like decline in corporate sales.
Therefore, pharmaceutical companies should do a good job of information collection and analysis, adjust their strategic layout in advance, and optimize product lines.
The restriction of drugs will lead to a cliff-like decline in corporate sales.
Therefore, pharmaceutical companies should do a good job of information collection and analysis, adjust their strategic layout in advance, and optimize product lines.
Efforts can be made to allow products to enter clinical guidelines and preferred varieties to reduce the probability of becoming auxiliary drugs; to reform marketing models and strengthen terminal development; to sort out product structure, and to shift the development focus from products that have a high probability of entering the national key monitoring catalog to curative effects Exact quality product.
Medical Network News, April 16 Recently, the Fujian Provincial Medical Insurance Bureau issued the "Notice on Announcement of the Second Batch of Medical Insurance Key Monitoring Drugs and List of Key Drugs".
Among them, 10 medical insurance drugs are under key monitoring and 59 are under special attention; the two types of lists are subject to dynamic management.
For key monitoring drugs, finding how to solve the survival crisis is the kingly way.
Among them, 10 medical insurance drugs are under key monitoring and 59 are under special attention; the two types of lists are subject to dynamic management.
For key monitoring drugs, finding how to solve the survival crisis is the kingly way.
Re-clinical evaluation
The first thing to do is to find out the problem with the drug being monitored.
For example, in my country, Oxiracetam is approved for memory and intellectual impairment caused by mild to moderate vascular dementia, senile dementia, and traumatic brain injury.
However, in the United States, Oxiracetam has been withdrawn.
Phase II clinical trial for the treatment of Alzheimer's disease.
Another example is the use of auxiliary medicines, which are likely to cause doctor-patient disputes.
In addition to prescribing medicines, doctors need to be cautious, and it is also necessary to conduct a new clinical evaluation.
For example, in my country, Oxiracetam is approved for memory and intellectual impairment caused by mild to moderate vascular dementia, senile dementia, and traumatic brain injury.
However, in the United States, Oxiracetam has been withdrawn.
Phase II clinical trial for the treatment of Alzheimer's disease.
Another example is the use of auxiliary medicines, which are likely to cause doctor-patient disputes.
In addition to prescribing medicines, doctors need to be cautious, and it is also necessary to conduct a new clinical evaluation.
In addition, a re-clinical evaluation may allow the unique value of the drug to be found in the clinical pathway, or it may be possible to lock in a more effective treatment plan in the new study of combination drugs.
Open up a "second battlefield"
For pharmaceutical companies, the restricted use of drugs due to key monitoring, ranging from a sharp decline in sales performance, to a rupture of the capital chain and falling to death.
However, the East is not bright and the West is bright.
In addition to public-level hospitals and public primary hospitals, there are also private hospitals, clinics, chain pharmacies , and single pharmacies.
Restricted varieties can open up a "second battlefield" and enter other channels.
First, consider switching from medical insurance drugs to self-funded drugs in public hospitals.
If it is an oral medicine that has been sold in hospitals for many years and has a solid market basis, it can be transferred to OTC channels.
However, the East is not bright and the West is bright.
In addition to public-level hospitals and public primary hospitals, there are also private hospitals, clinics, chain pharmacies , and single pharmacies.
Restricted varieties can open up a "second battlefield" and enter other channels.
First, consider switching from medical insurance drugs to self-funded drugs in public hospitals.
If it is an oral medicine that has been sold in hospitals for many years and has a solid market basis, it can be transferred to OTC channels.
In addition, it is possible to consider direct chain pharmacies with more than 30 stores.
Directly-operated chains have strong execution in price control, channel protection, and sales traceability, and can better cooperate with manufacturers to implement their sales intentions.
Directly-operated chains have strong execution in price control, channel protection, and sales traceability, and can better cooperate with manufacturers to implement their sales intentions.
Private hospitals, private clinics
Part of the restricted medicines do not completely lose their vitality.
On the contrary, they may be very useful in private hospitals and private clinics.
At present, the development threshold of private hospitals and private clinics is low, and the base is huge.
On the contrary, they may be very useful in private hospitals and private clinics.
At present, the development threshold of private hospitals and private clinics is low, and the base is huge.
The author believes that certain drugs with the potential to improve the quality of life (such as compound coenzyme for injection, calf serum deproteinized injection, troxerutin cerebroprotein hydrolysate injection), or varieties with fewer manufacturers (such as cerebroside and carnosine) Injection, invert sugar electrolyte injection, etc.
), these channels can be considered.
If medical insurance does not pay, pharmaceutical companies can also seek support from commercial insurance.
), these channels can be considered.
If medical insurance does not pay, pharmaceutical companies can also seek support from commercial insurance.
Change the route of administration
For restricted Chinese patent medicine injections, it is possible to consider changing the route of administration, new routes of administration such as transdermal absorption, enema, atomization, spraying and so on.
Some of the restricted Chinese medicine injections are from well-known families.
They have good production technology and purification technology.
A good horse is equipped with a good saddle.
The new drug delivery method can not only solve the sales problem of restricted medicines, but also improve the curative effect.
Some of the restricted Chinese medicine injections are from well-known families.
They have good production technology and purification technology.
A good horse is equipped with a good saddle.
The new drug delivery method can not only solve the sales problem of restricted medicines, but also improve the curative effect.
Adjust the variety structure
Pharmaceutical production enterprises to change totally dependent on a single product big habit pulled up the performance.
It is necessary to keep abreast of the market pulse, adjust its product line in time, continue to introduce new ones, "sell a batch, market a batch, develop a batch", and develop drugs with real therapeutic value.
It is necessary to keep abreast of the market pulse, adjust its product line in time, continue to introduce new ones, "sell a batch, market a batch, develop a batch", and develop drugs with real therapeutic value.
The wind started at the end of Qingping.
The restriction of drugs will lead to a cliff-like decline in corporate sales.
Therefore, pharmaceutical companies should do a good job of information collection and analysis, adjust their strategic layout in advance, and optimize product lines.
The restriction of drugs will lead to a cliff-like decline in corporate sales.
Therefore, pharmaceutical companies should do a good job of information collection and analysis, adjust their strategic layout in advance, and optimize product lines.
Efforts can be made to allow products to enter clinical guidelines and preferred varieties to reduce the probability of becoming auxiliary drugs; to reform marketing models and strengthen terminal development; to sort out product structure, and to shift the development focus from products that have a high probability of entering the national key monitoring catalog to curative effects Exact quality product.
Medical Network News, April 16 Recently, the Fujian Provincial Medical Insurance Bureau issued the "Notice on Announcement of the Second Batch of Medical Insurance Key Monitoring Drugs and List of Key Drugs".
Among them, 10 medical insurance drugs are under key monitoring and 59 are under special attention; the two types of lists are subject to dynamic management.
For key monitoring drugs, finding how to solve the survival crisis is the kingly way.
Among them, 10 medical insurance drugs are under key monitoring and 59 are under special attention; the two types of lists are subject to dynamic management.
For key monitoring drugs, finding how to solve the survival crisis is the kingly way.
Re-clinical evaluation
Re-clinical evaluation The first thing to do is to find out the problem with the drug being monitored.
For example, in my country, Oxiracetam is approved for memory and intellectual impairment caused by mild to moderate vascular dementia, senile dementia, and traumatic brain injury.
However, in the United States, Oxiracetam has been withdrawn.
Phase II clinical trial for the treatment of Alzheimer's disease.
Another example is the use of auxiliary medicines, which are likely to cause doctor-patient disputes.
In addition to prescribing medicines, doctors need to be cautious, and it is also necessary to conduct a new clinical evaluation.
For example, in my country, Oxiracetam is approved for memory and intellectual impairment caused by mild to moderate vascular dementia, senile dementia, and traumatic brain injury.
However, in the United States, Oxiracetam has been withdrawn.
Phase II clinical trial for the treatment of Alzheimer's disease.
Another example is the use of auxiliary medicines, which are likely to cause doctor-patient disputes.
In addition to prescribing medicines, doctors need to be cautious, and it is also necessary to conduct a new clinical evaluation.
In addition, a re-clinical evaluation may allow the unique value of the drug to be found in the clinical pathway, or it may be possible to lock in a more effective treatment plan in the new study of combination drugs.
Open up a "second battlefield"
Open up a "second battlefield" For pharmaceutical companies, the restricted use of drugs due to key monitoring, ranging from a sharp decline in sales performance, to a rupture of the capital chain and falling to death.
However, the East is not bright and the West is bright.
In addition to public-level hospitals and public primary hospitals, there are also private hospitals, clinics, chain pharmacies , and single pharmacies.
Restricted varieties can open up a "second battlefield" and enter other channels.
First, consider switching from medical insurance drugs to self-funded drugs in public hospitals.
If it is an oral medicine that has been sold in hospitals for many years and has a solid market basis, it can be transferred to OTC channels.
Hospital hospital hospital pharmacy pharmacy pharmacyHowever, the East is not bright and the West is bright.
In addition to public-level hospitals and public primary hospitals, there are also private hospitals, clinics, chain pharmacies , and single pharmacies.
Restricted varieties can open up a "second battlefield" and enter other channels.
First, consider switching from medical insurance drugs to self-funded drugs in public hospitals.
If it is an oral medicine that has been sold in hospitals for many years and has a solid market basis, it can be transferred to OTC channels.
In addition, it is possible to consider direct chain pharmacies with more than 30 stores.
Directly-operated chains have strong execution in price control, channel protection, and sales traceability, and can better cooperate with manufacturers to implement their sales intentions.
Directly-operated chains have strong execution in price control, channel protection, and sales traceability, and can better cooperate with manufacturers to implement their sales intentions.
Private hospitals, private clinics
Private hospitals, private clinics Part of the restricted medicines do not completely lose their vitality.
On the contrary, they may be very useful in private hospitals and private clinics.
At present, the development threshold of private hospitals and private clinics is low, and the base is huge.
On the contrary, they may be very useful in private hospitals and private clinics.
At present, the development threshold of private hospitals and private clinics is low, and the base is huge.
The author believes that certain drugs with the potential to improve the quality of life (such as compound coenzyme for injection, calf serum deproteinized injection, troxerutin cerebroprotein hydrolysate injection), or varieties with fewer manufacturers (such as cerebroside and carnosine) Injection, invert sugar electrolyte injection, etc.
), these channels can be considered.
If medical insurance does not pay, pharmaceutical companies can also seek support from commercial insurance.
), these channels can be considered.
If medical insurance does not pay, pharmaceutical companies can also seek support from commercial insurance.
Change the route of administration
Change the route of administration For restricted Chinese patent medicine injections, it is possible to consider changing the route of administration, new routes of administration such as transdermal absorption, enema, atomization, spraying and so on.
Some of the restricted Chinese medicine injections are from well-known families.
They have good production technology and purification technology.
A good horse is equipped with a good saddle.
The new drug delivery method can not only solve the sales problem of restricted medicines, but also improve the curative effect.
Some of the restricted Chinese medicine injections are from well-known families.
They have good production technology and purification technology.
A good horse is equipped with a good saddle.
The new drug delivery method can not only solve the sales problem of restricted medicines, but also improve the curative effect.
Adjust the variety structure
Adjust the variety structure Pharmaceutical production enterprises to change totally dependent on a single product big habit pulled up the performance.
It is necessary to keep abreast of the market pulse, adjust its product line in time, continue to introduce new ones, "sell a batch, market a batch, develop a batch", and develop drugs with real therapeutic value.
Pharmaceutical medicine pharmaceutical companies business enterprises Drugs Drugs DrugsIt is necessary to keep abreast of the market pulse, adjust its product line in time, continue to introduce new ones, "sell a batch, market a batch, develop a batch", and develop drugs with real therapeutic value.
The wind started at the end of Qingping.
The restriction of drugs will lead to a cliff-like decline in corporate sales.
Therefore, pharmaceutical companies should do a good job of information collection and analysis, adjust their strategic layout in advance, and optimize product lines.
The restriction of drugs will lead to a cliff-like decline in corporate sales.
Therefore, pharmaceutical companies should do a good job of information collection and analysis, adjust their strategic layout in advance, and optimize product lines.
Efforts can be made to allow products to enter clinical guidelines and preferred varieties to reduce the probability of becoming auxiliary drugs; to reform marketing models and strengthen terminal development; to sort out product structure, and to shift the development focus from products that have a high probability of entering the national key monitoring catalog to curative effects Exact quality product.
